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A B S T R A C T
Mesoporous vaterite CaCO3 crystals are nowadays one of the most popular vectors for loading of fragile bio-
molecules like proteins due to biocompatibility, high loading capacity, cost eﬀective and simple loading pro-
cedures. However, recent studies reported the reduction of bioactivity for protein encapsulation into the crystals
in water due to rather high alkaline pH of about 10.3 caused by the crystal hydrolysis. In this study we have
investigated how to retain the bioactivity and control the release rate of the enzyme superoxide dismutase (SOD)
loaded into the crystals via co-synthesis. SOD is widely used as an antioxidant in ophthalmology and its for-
mulations with high protein content and activity as well as opportunities for a sustained release are highly
desirable. Here we demonstrate that SOD co-synthesis can be done at pH 8.5 in a buﬀer without aﬀecting crystal
morphology. The synthesis in the buﬀer allows reaching the high loading eﬃciency of 93%, high SOD content
(24 versus 15 w/w % for the synthesis in water), and order of magnitude higher activity compared to the
synthesis in water. The enormous SOD concentration into crystals of 10−2 M is caused by the entrapment of SOD
aggregates into the crystal pores. The SOD released from crystals at physiologically relevant ionic strength fully
retains its bioactivity. As found by ﬁtting the release proﬁles using zero-order and Baker-Lonsdale models, the
SOD release mechanism is governed by both the SOD aggregate dissolution and by the diﬀusion of SOD mole-
cules thorough the crystal pores. The latest process contributes more in case of the co-synthesis in the buﬀer
because at higher pH (co-synthesis in water) the unfolded SOD molecules aggregate stronger. The release is bi-
modal with a burst (ca 30%) followed by a sustained release and a complete release due to the recrystallization
of vaterite crystals to non-porous calcite crystals. The mechanism of SOD loading into and release from the
crystals as well as perspectives for the use of the crystals for SOD delivery in ophthalmology are discussed. We
believe that together with a fundamental understanding of the vaterite-based protein encapsulation and protein
release, this study will help to establish a power platform for a mild and eﬀective encapsulation of fragile
biomolecules like proteins at bio-friendly conditions.
1. Introduction
The eye is rather an isolated organ, and the pathological processes
within it are preferably treated not via systemic but by local drug in-
take. Many drugs for the treatment of eye diseases are used in the form
of eye drops. However, only 1–5% of the drug penetrates the cornea
through the internal structures of the eye [1]. After instillation, a rapid
and large loss of the drug occurs due to its ﬂushing from the surface of
the eye with a tear and with blinking [2]. To get into the internal
structures of the eye, the drug must penetrate through the cornea,
where the epithelium of the cornea is the most diﬃcult barrier to
overcome. Densely packed cells of multilayered epithelium work as a
selective barrier for low-molecular-weight substances and prevent the
diﬀusion of macromolecules. The duration of contact of the drug with
the cornea is usually 5–25min [3], which greatly limits the eﬀective-
ness of the action of aqueous solutions of drugs.
In the last 20 years, more and more works have appeared, in which
it is proposed to use more eﬃcient systems for the delivery of
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ophthalmic drugs to the eye. These include, ﬁrst and foremost, the use
of drug complexes with cyclodextrins [4], the combined use of oph-
thalmic drugs with agents that enhance the penetration of drugs
through biological membranes (EDTA, taurocholic and capric acids)
[5], the use of polymer gels [6], colloidal systems containing a drug
immobilized on a carrier. The latter include systems with drugs em-
bedded in liposomes [7] and nanoparticles of diﬀerent nature [8].
Despite of signiﬁcant advancements in ocular drug delivery, low
duration of the contact of drug delivery systems with the cornea re-
mains challengeable. One of the promising strategies is the use of mu-
coadhesive systems for which the residence time of the drug carriers is
governed not by tear but by mucus turnover; hence drug retention is
substantially improved [9].
From the other hand, in the recent years growing demand on the
biopharmaceuticals used for the treatment of indications in the eyes has
emerged. Mainly, this is because ophthalmic macromolecular drugs
often allow for eﬀective therapy with fewer side eﬀects [10].
The gap between the discovery of modern macromolecular drugs
and their utilization for ophthalmological applications is largely created
by the lack of proper drug delivery technologies because nearly all
existing ocular delivery systems have been tailored for the small mo-
lecules. This provokes the urgent need of the development of drug
delivery systems suitable for macromolecular therapy [10], e.g. em-
ploying promising ophthalmological protein superoxide dismutase
(SOD).
The enzyme SOD has attracted an attention of scientists since the
middle of the twentieth century. Dismutation of an oxygen radical into
hydrogen peroxide with SOD is often called primary protection, since
this enzyme prevents the formation of free radicals. Antioxidants, SOD
in particular, are known to be beneﬁcial in the treatment of various
diseases related to an oxidative stress. Thus, SOD was reported to re-
duce inﬂammation [11], accelerate the healing of skin lesions caused
by burns, systemic lupus erythematosus, and herpes [12–14], protect
cultured human neurons under oxidative stress [15], reduce ischemia-
reperfusion injury [16–18], inhibit angiotensin II intra-neuronal sig-
naling [19], prolong viability of β-cells [20], be eﬀective in the treat-
ment of rat adjuvant arthritis [21], etc.
One of the possible applications of SOD is the treatment of the
various eye diseases associated with oxidative stress. Thus, SOD was
used for the treatment of lens-induced and bovine albumin-induced
uveitis in rabbits [22,23], as well as for the treatment of acute corneal
inﬂammation in animals induced by sodium hydroxide [24,25]. SOD
was employed for the treatment of severe experimental allergic uveitis
induced by retinal S antigen in rats [26], while poly(ethylene glycol)-
(PEG-) modiﬁed SOD was employed for the treatment of the same type
of uveitis in guinea pigs [27].
When systemically administered, SOD signiﬁcantly loses its activity
due to the inﬂuence of proteolytic enzymes and is rapidly eliminated
from the circulatory system through the kidneys [28–30]. In the recent
years, a signiﬁcant amount of research aimed at the increase of the
bioavailability of SOD for both systemic and local administration.
Various methods of SOD modiﬁcation are used to protect the enzyme
against adverse environmental eﬀects, to prolong the release and
achieve the targeted delivery. These methods include: chemical mod-
iﬁcation (PEGylation [31], binding to lecithin [32]), inclusion in lipo-
somes [33], as well as micro- and nano-encapsulation of the enzyme
[18,34–36], enzyme immobilization using the layer-by-layer assembly
[37].
Cheap, biocompatible and biodegradable CaCO3 micro- and nano-
crystals are widely used in the ﬁeld of encapsulation as matrices for
assembly of polymer-based carriers as well as containers for the in-
clusion of various drugs [38–47]. Special attention is paid to the va-
terite modiﬁcation of CaCO3. Vaterite crystals can easily be synthetized
in laboratory and typically represent spherical particles with a con-
trolled size from hundreds of nanometres to tens of micrometres [43].
Moreover, not only the dimensions of the crystals but also a shape [48]
and the internal porosity [49] can be adjusted. The highly porous sur-
face of the vaterite crystals allows the inclusion of signiﬁcant amounts
of biologically active substances, including labile proteins and enzymes
[38,39]. A number of approaches including co-synthesis, inﬁltration,
and solvent exchange have been introduced for the loading of proteins
into the vaterite crystals in order to form protein-based nano- and
micro-particles [50–52]. In addition, the crystals have been reported as
eﬀective carriers for diagnostics, e.g. using Raman spectroscopy
[53,54] and external manipulation [55], as sacriﬁcial templates to as-
semble polymer-based functional structures from multilayers [56] and
from other functional molecules such as PEG and poly-N-iso-
propylacrylamide [57,58]. The crystals can take multiple roles being
not only sacriﬁcial templates utilized to formulate polymer particles
with a well-deﬁned structure, but also can serve as a source of calcium
and as porogens to assemble alginate gels with a tuned internal porosity
and encapsulated molecules of interest such as proteins [59,60].
The introduction of proteins and enzymes during the formation of
vaterite crystals (co-synthesis) allows to achieve a high inclusion, much
exceeding the inclusion when adsorbed on the surface of preformed
crystals [30,44,61–69]. However, due to alkaline conditions during the
co-synthesis (pH more than 10), labile proteins and enzymes can sig-
niﬁcantly lose their bio-activity [70].
In the study [36], alginate granules were obtained, including those
based on vaterite microcrystals containing SOD and inhibitors of pro-
teolytic enzymes. The model system shows the possibility of utilizing
such a system for oral use and protection from the action of proteolytic
enzymes. However, the features of the interaction of SOD with vaterite
microcrystals, the preservation of the enzyme activity and the me-
chanism of SOD release from crystals have not been investigated.
In addition to the obvious advantages, most of the aforementioned
carriers have a number of disadvantages including the complexity of
the synthesis, the high costs for the synthesis, and a potential toxic
eﬀect of the carrier. Calcium carbonate microcrystals are deprived of
these disadvantages. In addition, high mucoadhesiveness of vaterite
microcrystals which has recently been demonstrated in [69] and [71]
might promote the retention of the microcrystals in the eye due to the
binding to the ocular mucus. Simplicity of the synthesis, mild synthesis
and mild crystal decomposition conditions, a large speciﬁc surface area
– all this makes the crystals as perfect carriers for ophthalmic drugs in
general and for SOD in particular.
In this work we investigate whether SOD can eﬀectively be en-
capsulated into the vaterite crystals keeping its bioactivity and oﬀering
controlled release opportunities. For that we investigated the loading of
the SOD in water and in the buﬀer (ﬁnal pH 8.4) and compared the
loading performance by the analysis of thermodynamic parameters of
the encapsulation process, polymorph phase of the crystals formed as
well as SOD bioactivity retention and the release of SOD at physiolo-
gically relevant ionic strength. Using modern techniques and ap-
proaches we conclude about the SOD loading and release mechanisms.
This study is indispensable for getting fundamental knowledge on en-
capsulation and controlled release of proteins and other bioactive fra-
gile biomolecules employing the vaterite CaCO3 crystals.
2. Experimental section
2.1. Materials
CaCl2 99% was purchased from «Biomedicals» ICN, Inc. (USA);
Na2CO3 99.8% was purchased from «Pharma» (Russia); recombinant
human superoxide dismutase-1 was purchased from «Enzyme
Technology» (Russia); TRIS, NaCl 99% and Coomassie Brilliant Blue G-
250 were purchased from «Sigma-Aldrich (USA); EDTA was purchased
from «Reakhim» (Russia). Other chemicals were all purchased from
«Sigma», Germany. All chemicals used in this study were of analytical
grade and used without puriﬁcation. Ultrapure water was used for all
experiments.
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2.2. Preparation of the SOD-loaded CaCO3 crystals
The co-synthesis method [68] with some modiﬁcations was em-
ployed to encapsulate the SOD into the crystals. Before use, all salt
solutions were ﬁltered (RC 0.20mm ﬁlter, Corning Inc., USA). Brieﬂy,
1ml of 1M CaCl2 was added to 3ml of solution with dissolved SOD (in
water or in 100mM TRIS-buﬀer with pH 7.5) to achieve the desired
protein concentration in the mixture of 0.5–6mg/ml and ﬁnal buﬀer
concentration of 60mM. The concentration of the TRIS buﬀer was used
as per above, if not speciﬁcally mentioned. 1ml of 1M Na2CO3 solution
was rapidly added and the mixture under agitation on a magnetic stirrer
(400 rpm) at room temperature for 45 s. After that, the agitation was
stopped, and the reaction mixture was left without stirring for 15min,
allowing preformed amorphous primary precipitates of CaCO3 to
transform slowly into vaterite crystals. Finally, the supernatant was
discarded, 5ml of deionized water was added to the pellet, stirred and
after 15min incubation the washing solution was removed. This
washing procedure was repeated twice. The precipitated CaCO3 mi-
crocrystals were lyophilized and stored in a closed container. Empty
crystals (without SOD) were prepared in using the same protocol and
solutions but without SOD.
2.3. Determination of protein content
Using a UV spectrophotometer (Cary 50 Conc, «Varian», USA), two
independent methods were carried out to determine the SOD con-
centration: the Bradford protein assay [72] and the measurement of the
optical density of the SOD at a wavelength of 280 nm. All measure-
ments were performed in triplicates. To determine the protein loading
eﬃciency into the crystals, the loaded SOD amount was calculated from
the total amount of added enzyme and that measured in the super-
natant of the crystals after preparation and the washing steps.
2.4. Assessment of the enzyme biological activity
To determine the speciﬁc enzymatic activity of recombinant human
superoxide dismutase an inhibition of autoxidation SOD reaction by
pyrogallol [73] was assessed. The SOD-containing solution (native SOD
solution or the solution obtained after dissolution of CaCO3 crystals in
200mM EDTA) was diluted with water by the dilution factor from 10 to
4000. 20 μl of the obtained solution was added into a well. Further,
160 μl of 50mM TRIS, pH 8.2, containing 1.25mM DTPA, were added.
Pyrogallol was ﬁrst dissolved in acetone to a ﬁnal concentration of
5mg/ml and diluted ten times with water immediately before the
measurement. The reaction was initiated by addition of 20 μl of the
pyrogallol solution. The mixture was rapidly stirred and the optical
density was measured at 420 nm for 5min. 180 μl of 50mM TRIS, pH
8.2, containing 1.25mM DTPA, with 20 μl of pyrogallol was used as
control. The measurements were carried out on a microplate reader
Inﬁnite M200, «Tecan», Switzerland.
2.5. Protein adsorption
The adsorption isotherms for SOD loading into the crystals by co-
synthesis in water or in the TRIS buﬀer were constructed and the
thermodynamic parameters of the adsorption process were calculated.
The initial SOD concentration (C0) ranged from 0.5mg/ml to 6mg/ml.
Equilibrium protein concentrations (Ce, mg/ml) were determined from
the loading eﬃciency. To determine the adsorption equilibrium con-
stants, the Langmuir adsorption isotherm model was used [68]. To
calculate the input values of adsorption and the adsorption equilibrium
constant, the experimental isotherms were linearized by plotting the Ce
vs Ce/qe.
2.6. Synthesis of FITC-labeled SOD
To a solution of 2mg/ml SOD in 0.5M carbonate buﬀer, pH 9, a
solution of 0.1 M FITC in carbonate buﬀer, pH 9, was added dropwise
with constant stirring until the protein:FITC molar ratio was adjusted to
be 1:2. The resulting solution was incubated for 4 h in a darkness, and
then dialyzed twice against 50mM TRIS, pH 7.0.
2.7. Confocal laser scanning microscopy (CLSM)
The dried crystals were placed in water and transferred to a glass
Petri dish and further examined on a Nikon Eclipse Ti-E CLSM micro-
scope with the confocal module A1 (Nikon Corporation, Japan). 488 nm
wavelength of the laser and an Apo TIRF 60x/1.49 oil lens were used.
The ﬂuorescence has been measured in the wavelength range of
500–550 nm. A series of optical sections were obtained and a three-
dimensional reconstruction was performed (horizontal projection of the
optical sections on the plane). The images were analyzed by the Nis-
Elements program and also using the ImageJ to obtain the ﬂuorescence
proﬁle.
2.8. Scanning electron microscopy (SEM)
The surface structure of particles and their shapes were studied by
SEM using LEO SUPRA 50 VP (Germany) with the VPSE detector. The
optimum acceleration voltage was chosen at 20–21 kV, the 4th scan-
ning speed was used, and the noise was removed by integration along
the line. To carry out the experiment, the crystals were previously
lyophilized and placed on the adhesive tape.
2.9. X-ray diﬀraction analysis
X-ray experiments were performed on a diﬀractometer with a ro-
tating anode Rigaku D/MAX 2500 (Rigaku, Japan) in the reﬂection
mode (Bragg-Brentano geometry) using Cu Kα radiation and a graphite
monochromator. Parameters of the X-ray generator in the experiment
are: accelerating voltage 50 kV, cathode heating current 250mA (total
power of the X-ray tube is 12.5 kW). Alignment of the optical scheme of
the diﬀractometer and adjustment of the parameters of the dis-
criminator ampliﬁer were carried out automatically under the control
of the diﬀractometer software. The diﬀraction patterns for phase ana-
lysis at room temperature were taken in quartz cuvettes using a stan-
dard sample holder. The spectrum was collected in a continuous θ–2θ
scanning mode with a detector speed of 3°/min and averaging para-
meter of 0.02° on a 2θ scale. The shooting interval was from 15 to 70°
on a scale of 2θ. To determine the parameters of a unit cell, the survey
was conducted using an internal standard (germanium). The data was
processed using the Winxpow software package and the ICDD PDF 2
database.
2.10. In vitro release of SOD
In a standard protocol, 10mg of the dried crystals with co-synthe-
sized SOD were dispersed in 1mL of a 150mM NaCl solution, then the
suspensions were incubated for various time intervals (10–200min, 24,
36 h) at room temperature. After the incubation, the suspensions were
centrifuged at 9000 rpm for 5min, and the SOD concentration and
activity were determined in the supernatant. All experiments were
performed in triplicates.
2.11. Dynamic light scattering (DLS) measurements
The average hydrodynamic diameter and polydispersity index were
measured by DLS using a Zetasizer Nano ZS instrument (Malvern Co.,
Ltd., UK). The measurements were carried out at a ﬁxed angle of 90° at
25 °C repeatedly to obtain statistically reliable results. The data was
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automatically processed using Zetasizer v.7.03 software.
3. Results and discussion
3.1. Optimization of vaterite crystal synthesis
Our preliminary studies demonstrated that the activity of SOD
(32 kDa, pI 4.5), signiﬁcantly decreases when the enzyme is incubated
in TRIS buﬀer solution with the pH above 8.5 (Fig. 1a). At pH 8.5 the
activity retention is about 90%, whereas at pH 9.5 the only 30% is
retained. Therefore, in order to preserve the activity of the enzyme, the
preparation of vaterite crystals, by the standard mixing of CaCl2 and
Na2CO3 solutions, should be carried out at pH below 8.5.
In accordance with Lewis theory of acids and bases, CaCO3 is a ty-
pical conjugate base and is prone to a partial hydrolysis in aqueous
solution and has a pKa of about 9. Vaterite CaCO3 has solubility in
water of about 1.3·10−5 M, and therefore crystal hydrolysis results in an
elevated pH value of aqueous suspension of CaCO3 crystals. As a result,
under standard crystal synthesis in water, the pH of the suspension
rapidly increases to a value more than 10, reaching a ﬁnal value of 10.3
(Fig. 1b).
A simple option to keep the pH constant during the synthesis pro-
cess is to perform the synthesis in a buﬀer (usually the synthesis is done
in water). First we have assessed the variation of pH value during the
synthesis when the synthesis has been performed in 60mM TRIS buﬀer,
pH 7.5. As it can be seen from Fig. 1b, under these conditions, the pH of
the medium increases during the formation of the vaterite micro-
crystals, but did not exceed 8.5, reaching a ﬁnal pH of about 8.4.
In order to understand whether the presence of the TRIS buﬀer
during the crystal synthesis can aﬀect the crystals properties, the crystal
morphology has been tested. The crystal size has not been signiﬁcantly
aﬀected by the presence of the buﬀer. The average diameter of the
crystals prepared in water and in the TRIS buﬀer are 3.8 ± 0.3 μm and
3.4 ± 0.5 μm, respectively. In order to probe an eﬀect of the TRIS
buﬀer on the crystal morphology, the crystals have been prepared in the
presence of high concentration of the buﬀer, i.e. in 120mM TRIS buﬀer
with the same pH. SEM images of the crystals prepared in water and in
the buﬀer are shown in Fig. 2a and b, respectively. The crystals look
rather similar, however, the surface morphology can only be assessed
by a deep look. Enlarged images of the crystal surface are presented in
Fig. 2c,d. The morphology represents a channel-like structure with the
channel width (D) to be deﬁned according to the the designated lines in
the enlarged images. The average values of the channel widths for the
crystals prepared in water and the buﬀer have been found to be
33 ± 9 nm and 37 ± 7 nm, respectively. These values are not
statistically diﬀerent proving that the presence of the TRIS buﬀer does
not aﬀect the surface morphology of the crystals. Based on the main
results of in the study [49], the external morphology of the crystals
scales with pores in the internal volume of the crystals. This allows one
to assume that the internal structure of vaterite crystals (porosity) is not
inﬂuenced by the presence of the TRIS buﬀer. This gives a good option
for the synthesis of vaterite crystals in TRIS buﬀer at the ﬁnal pH 8.4,
that to some extent exceed the physiological pH value, however, is by
much fare away from the alkaline pH 10.3 as for the synthesis in water.
To further test whether the TRIS buﬀer can aﬀect the internal
structure of the crystals, the X-ray diﬀraction analysis has been per-
formed. This analysis allows to identify the polymorph form of the
CaCO3, i.e. the porous spherical vaterite and non-porous cubic calcite
forms (Fig. 3, top). According to the results of the X-ray analysis (Fig. 3,
bottom), the presence of the TRIS buﬀer did not lead to an increase in
the calcite content, and the content of the vaterite was not less than
90%. This corresponds to a rather small number of calcite crystals
prepared during the synthesis, however, the majority of the crystals
obtained belong to the vaterite polymorph.
3.2. Loading of SOD into crystals
The preparation of vaterite crystals with SOD was carried out in
60mM TRIS buﬀer or in water to have ﬁnal pH of 8.4 and 10.3, re-
spectively. For that, SOD was pre-mixed with a solution of CaCl2, and
then a solution of Na2CO3 was added. The concentration of SOD in the
suspension was varied from 0.1 to 6mg/ml. Even at a high con-
centration of the enzyme, no change in the phase composition of the
crystals was observed (no increased content of calcite was present, data
not shown).
CLSM analysis demonstrated rather homogeneous distribution of
SOD-FITC co-synthetized in the vaterite crystals (Fig. 4). It is hard to
make qualitative conclusions regarding a real distribution of the en-
zyme into crystals because of potential optical eﬀects associated with
the penetration of a light into porous vaterite crystals. However, a
strong ﬂuorescence from the whole volume of the crystal (Fig. 4c) can
only indicate that the crystal is likely uniformly loaded with the SOD.
No sterical diﬃculties can be expected for the diﬀusion of SOD
molecules into pores of the crystals (typical pore sizes are in the range
5–30 nm [68]). According to the DLS data (Fig. 5a,b), the size of the
SOD molecule in water and in the TRIS buﬀer is about 6 nm, so the
enzyme is able to penetrate into the pores of crystals. At the same time,
the uptake of SOD via the co-synthesis may have a mechanism that does
not involve a direct diﬀusion of SOD through the pores but may be
based on the embedding of SOD molecules during the crystal growth. In
Fig. 1. (a) The residual SOD biological activity after 1 h incubation in 0.1M TRIS with pH values ranging from 7 to 10. Protein concentration 1mg/ml. (b) The
evolution of the pH in the working medium during synthesis of vaterite CaCO3 crystals in water and in TRIS buﬀer.
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order to better understand the loading mechanism, the thermodynamic
parameters have been extracted from the adsorption isotherms con-
structed for the SOD co-synthesis as discussed below.
The eﬀect of SOD concentration on the inclusion in microcrystals in
water and in the TRIS buﬀer has been studied (Fig. 6). After the de-
termination of the protein concentration in the supernatants, the
amount of SOD in the crystals was calculated and referred to the total
amount of the enzyme in order to work out the encapsulation eﬃ-
ciency. As it can be seen from Fig. 6a, with the increase of the protein
concentration from 0.5 to 6mg/ml, the encapsulation eﬃciency de-
creased from 92 to 35% and from 93 to 52% for synthesis in water and
in TRIS buﬀer, respectively. This trend collaborates well with the one
observed for the co-precipitation of other proteins (e.g. [70]) and can
be explained by the saturation of the microcrystals. These results de-
monstrate high eﬃciency (up to 93%) to uptake the SOD from the so-
lution by the co-synthesis.
Taking into account the amount of the protein in the crystals and
the mass of CaCO3 after the synthesis, the adsorption isotherms for the
SOD were calculated by plotting the equilibrium adsorption capacity
(qe) against the equilibrium SOD concentration Ce (Fig. 6b). As in our
previous studies [68], for the analysis of isotherms, the adsorption









where qe is the equilibrium adsorption, mg/g CaCO3; Ce – equilibrium
protein concentration, mg/ml; qm – maximum adsorption capacity of
the crystals for SOD, mg/g; Ka – equilibrium constant, ml/mg.
The thermodynamic parameters were extracted after presenting the
equation above as Ce vs Ce/qe as shown in the Table 1.
The maximum adsorption capacity of the crystals for SOD for the
synthesis in the TRIS buﬀer was more than 50% times higher than that
obtained for the synthesis in water (240 and 150mg of SOD per g of
CaCO3, respectively). The concentration of the SOD in crystals achieved
by the synthesis in the buﬀer is about 1.6 times higher than the max-
imum adsorption capacity, i.e. 380mg/ml (or ca 10−2 M), taking into
account that the density of vaterite is 1.6 g/cm3 [39]. This extremely
high concentration (about a third of the concentration of SOD in a pure
solid SOD) can only be explained by an aggregation of SOD molecules
inside the crystal. Very high loading has previously been observed for
catalase loading into the crystals via co-synthesis [68] that has been
driven by Ca2+-mediated catalase aggregation during the ﬁrst step of
the co-synthesis procedure (catalase mixing with CaCl2). The SOD has a
strong tendency to aggregate in the presence of calcium ions [74] and
we assume that it is embedded into the crystals in the aggregated state.
While the intermolecular interactions between SOD molecules ex-
plain well the high loading capacity of vaterite microcrystals in respect
to SOD in general, the pronounced diﬀerence between the co-synthesis
in TRIS buﬀer and in water can be explained from the point of view of
electrostatic attraction. Apparently, this high loading in the buﬀer was
likely facilitated by stronger electrostatic interactions between the ne-
gatively charged SOD (pI 4.5) and the microcrystals that have a greater
positive surface charge at a lower pH according to the following study
[75]. At the same time, the reciprocal of the adsorption equilibrium
constant, corresponding to the equilibrium concentration when q= qm/
2, had a higher value for the loading in TRIS buﬀer. This (as can ob-
viously be concluded from the comparison of Ka) indicates a low
strength of binding of SOD to the crystals in the presence of TRIS
compared to the synthesis in water. At the same time, the qm is sig-
niﬁcantly higher for the synthesis in TRIS (Table 1). This can be ex-
plained by a formation of multilayers of SOD (SOD aggregates) during
the loading into the crystals. This will result in a deviation from the
Langmuir model (assumes a monolayer formation). However, this can
be explained as the following: the more SOD is adsorbed forming an
aggregate, the less strong is the formation of new SOD layers assuming
that the SOD-crystal interaction is stronger compared to the SOD-SOD
one. An alternative adsorption model for the SOD loading has not been
used here due to a good ﬁtting to the Langmuir model and a typical
proﬁle of the adsorption isotherm obtained for the Langmuir adsorption
phenomenon. However, as described above, the deviation from the
Langmuir model can take place.
The Gibbs energy for the SOD co-synthesis was calculated using the
equation:
= −ΔG RT Kln a (2)
where R is the universal gas constant, 8.31m2× kg× s−2×K−1× J/
(mol×K−1); T is the temperature, K; Ka – equilibrium constant, M−1.
The negative values of the Gibbs energy change for the co-synthesis
in water and in the TRIS buﬀer show a signiﬁcant shift in the equili-
brium towards SOD adsorption. These values are lower compared to
those obtained for the co-synthesis of the protein catalase. [68] From
the other side, the Ka values for the co-synthesis of SOD in water (Ka in
this study is ca 104M) is almost two orders of magnitude lower than
Fig. 2. SEM images of CaCO3 microcrystals
prepared in water at pH 10.3 (a) and in 0.2M
TRIS-buﬀer at pH 8.2 (b). Scale bars are 1 μm.
(c) and (d): top views on surface areas inside
the designated rectangles in (a) and (b), re-
spectively. Pore diameters (D1 and D2) have
been estimated as illustrated in (c) and (d),
respectively. D1= 33 ± 9 nm (n=40) and
D2= 37 ± 7 nm (n=40) are statistically not
diﬀerent.
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Fig. 3. (top) SEM image of CaCO3 crystals prepared in water demonstrates a porous nature of spherical vaterite crystals and non-porous calcite crystal (depicted with
an arrow). The scale bar is 2 μm. (bottom) XRD spectra for crystals prepared in water (a) and in TRIS buﬀer (b) as well as the SOD-containing crystals after 24 h of
incubation in 150mM NaCl; SOD loading concentration 1mg/ml (c). (For interpretation of the references to colour in the text, the reader is referred to the web
version of this article.)
Fig. 4. Fluorescence (a) and light transmittance (b) CLSM images of vaterite CaCO3 crystals with co-synthetized SOD-FITC. SOD loading concentration 1mg/ml.
Scale bars are 5 μm. Fluorescence proﬁle (c) is taken across the white line taken in (a). Background ﬂuorescence is subtracted to get the ﬂuorescence proﬁle.
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that for catalase (5× 105M). [68] Most probably, this can be explained
by diﬀerent aﬃnity of proteins to the CaCO3 surface. It is of note that
study [68] also barely touched the question of the retention of protein
activity after EDTA-mediated dissolution of vaterite cores. However,
securing bio-activity under physiologically relevant conditions seems to
be a crucial aspect for biomedical applications of CaCO3-based delivery
systems. Herein, further we focus on the retention of SOD activity after
the co-synthesis and will make a speciﬁc focus on understanding of SOD
release mechanism and kinetics in the solution simulating ionic
strength of most of biological ﬂuids (considered in the Section 3.4).
Fig. 5. DLS intensity weighted distribution of SOD hydrodynamic diameters for the SOD in water (a) and in 0.1M TRIS buﬀer (b) as well as SOD released from the
crystals after 10min (c) and 24 h (d) of incubation (the left spectra in (c,d) correspond to initial SOD distribution in the TRIS buﬀer). The SOD is loaded into the
crystals in the TRIS buﬀer at the protein concentration 1mg/ml.
Fig. 6. (a) Eﬃciency of SOD adsorption depending on the initial SOD concentration, for microcrystals obtained in water and in the TRIS buﬀer. (b) Adsorption
isotherms for SOD loading by co-synthesis in water and in the TRIS buﬀer (solid lines are the ﬁtting curves according to parameters in Table 1).
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3.3. SOD activity retention after crystal dissolution
The study of the retention of the activity of SOD co-synthetized in
this study under diﬀerent conditions is of particular interest for SOD
applications. First question to be faced is whether the SOD can retain its
activity after dissolution of the crystals. This is important since the
vaterite crystals are generally used as sacriﬁcial templates to be
eliminated (dissolved) for the formulation of polymer-based particles.
According to conventional approaches, to study the retention of the
SOD activity, vaterite microcrystals are dissolved using an equimolar
amount of EDTA followed by the determination of the SOD activity by
the indirect method based on the inhibition of the pyrogallol oxidation
[73]. To obtain the activity retention, the SOD activity measured after
crystal elimination was compared to that of SOD dissolved in water
(taken as 100%). For SOD co-synthetized in the TRIS buﬀer, the re-
tention of activity was found to be 48 ± 3%. This is 8 times higher
than the activity for the enzyme co-synthetized in water (activity re-
tention only 6 ± 2%). This demonstrates a signiﬁcant increase in the
retention of SOD activity for the crystal synthesis in the TRIS buﬀer as is
likely due to a lower pH for the co-synthesis in the buﬀer compared to
that in water.
A rather signiﬁcant reduction of SOD activity for the synthesis in
TRIS buﬀer (almost twice, activity retention 48 ± 3%) may be attrib-
uted to the eﬀect of EDTA on the activity of the enzyme, whose active
center includes copper. This phenomenon was also observed for other
enzymes that have metal ions in their active center [70]. In order to
better understand the reason of SOD activity reduction after crystal
dissolution, the release of SOD from crystals and the activity of the
released SOD have further been evaluated.
3.4. SOD release from crystals
The kinetics of the protein release from the crystals was studied in
150mM NaCl solution in order to simulate ionic strength typical for
most of biological ﬂuids. The SOD release proﬁle shows a burst (ca 30%
released) within the ﬁrst 10–20min followed by a sustained release
reaching the plateau at about 100min of the release time (Fig. 7). Re-
lease proﬁles for the SOD co-synthetized in water and in the TRIS buﬀer
are rather similar with a quicker release at the burst for the synthesis in
the buﬀer. Interestingly, the release proﬁles reach a well-deﬁned pla-
teau (in about 100min), however, this corresponds to the release of
about 80–90% of the loaded enzyme. Most probably the equilibrium
between soluble and adsorbed SOD is reached and therefore the com-
plete release does not take place. Only after 24 h of incubation, the
complete release has been observed (Fig. 7) that is explained by re-
crystallization of vaterite crystals to non-porous calcite and release of
all SOD molecules out of the crystal pores (Fig. S2). The recrystalliza-
tion of vaterite to calcite after 24 h of incubation was also conﬁrmed by
X-ray diﬀraction analysis (Fig. 3, bottom, c).
As a next step, the activity of the released SOD has been assessed.
Fig. 8 shows the amount of the released SOD, the activity retention for
the released SOD and SOD incubated in solution of 0.15M NaCl for
various time intervals. After almost 80% of the total loaded SOD has
been released from crystals in 100min incubation, the SOD activity
retention was very high (about 85%). However, the enzymatic activity
after 24 and 36 h of release has been signiﬁcantly reduced giving the
retained activity of about 50 and 30%, respectively. Similar trend in the
reduction of the bioactivity for the SOD has been observed for the SOD
solution in 0.15M NaCl stored for the same period of time as for the
release experiment (Fig. 7). This indicates that the SOD released at
physiological ionic strength from the vaterite crystals keeps its bioac-
tivity. However, long time storage of the enzyme in the presence of salt
results in reduction of the bioactivity. This result supports the as-
sumption that the presence of EDTA is most probably the reason of the
reduction of the SOD activity after dissolution of the SOD-containing
vaterite crystals (see the section above).
DLS investigation of the SOD size after the enzyme release from the
crystals have been performed to examine whether the SOD molecules
are aggregated or stay as single molecules. The aggregation would in-
dicate the sticking of the molecules to each other as a result of un-
folding due to a reduction of the bioactivity observed and described
above. Fig. 5c,d show the intensity weighted distribution of
Table 1
Thermodynamic parameters for SOD loading into vaterite crystals.
Crystal preparation qm, mg/g Ka−1, mg/ml ΔG, kJ/mol
in water 150 ± 6 0.22 ± 0.01 −29 ± 1
in 60mM TRIS 240 ± 8 0.37 ± 0.01 −29 ± 1
Fig. 7. Kinetics of SOD release in 150mM NaCl from vaterite crystals synthe-
tized in water and in the TRIS buﬀer.
Fig. 8. The amount of SOD released from the crystals (a), the retention of en-
zymatic activity for SOD released from crystals in 150mM NaCl (b) and for SOD
solution in 150mM NaCl stored for the same time as the release time (c). SOD
synthesis is performed in the TRIS buﬀer using the SOD loading concentration
1mg/ml.
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hydrodynamic diameters for SOD released from the crystals after
10 min and 24 h. The SOD molecules released after 10min stay as single
molecules (similar DLS proﬁles as for the SOD in water or in the TRIS
buﬀer, Fig. 5a,c). However, the SOD molecules released from the
crystals after 24 h possess a clear aggregation behavior as can be con-
cluded from the well-deﬁned shoulder on the DLS proﬁle (Fig. 5d). This
shows only a trend and one cannot conclude about the size of the ag-
gregates formed, however, strong indicators of the aggregation of SOD
molecules take place. Thus, the DLS results are in line with the ob-
servation of the reduction of SOD bioactivity. The activity reduction is a
result of unfolding of the protein followed by enhancing the hydro-
phobicity of the protein surface and ﬁnally intermolecular protein ag-
gregation.
3.5. Modeling the SOD release kinetics
The ﬁndings described above strongly indicate that the SOD is
present in the crystals as aggregates but releases as single molecules
keeping almost completely its bioactivity. To better understand the bi-
modal SOD release proﬁle (Fig. 7) and to prove whether there is a link
between the aggregated state of the enzyme in the crystals and the SOD
release performance, a couple of release models have been applied to ﬁt
the results of the release experiments.
We propose that the release can be limited either by the rate of the
dissolution of SOD aggregates inside the crystal pores or by the diﬀu-
sion of single SOD molecules through the crystal pores. The experi-
mental release data (Fig. 7) have been ﬁtted by two release models
corresponding to the above.
Bearing in mind that the concentration of SOD inside the micro-
crystals (ca 380mg/ml) is much higher than SOD solubility in water, it
was reasonable to assume above that SOD exists in the form of ag-
gregates with compactly packed SOD molecules. The size of such ag-
gregates cannot exceed the size of the crystal pores, so it is within a few
tens of nm and thus a single aggregate should be made of tens to
hundreds of SOD molecules at most. The dissolution of compactly
packed structures like nanocrystals is generally described by the zero
order reaction [76,77]. This is because the high surface area possessed
by the nanocrystals (compared to the large crystals of μm-dimensions)
results in a quick nanocrystal solvation and the increase in the con-
centration of the surrounding solution achieving a supersaturated state
at the initial stage of the dissolution [78]. In this study, the SOD ag-
gregates inside the crystals will behave similar to the nanocrystals de-
scribed above due to the size of the aggregates and to describe the re-
lease kinetics, one can apply the zero-order kinetical equation:
− =q q kttmax (3)
where qt and qmax – cumulative amount of SOD released at time t and
the maximum released amount, respectively, (mg/g); k – release rate
constant, (mg/g/min).
From the other hand, the model proposed by Baker and Lonsdale
can also be applied for our case. This model describes the release ki-
netics of the drug (SOD) that is encapsulated into the matrices of a
spherical shape (vaterite CaCO3) and is loaded into extremely high





















D – eﬀective diﬀusion coeﬃcient of SOD within the vaterite micro-
crystal; R – radius of the CaCO3 crystal; cs – SOD solubility; c0 – SOD
initial concentration of SOD loaded into the crystal; kB-L – constant.
Zero-order kinetics is applicable for initial stages of the release and
has been used for the ﬁrst ca 50% of SOD release and the Baker and
Lonsdale model has assumed the maximum release as per the plateau
well-deﬁned after ca 140min of release (Fig. 9).
The mathematical ﬁtting of these two models to the SOD release
kinetics is shown in Fig. 9; parameters of the ﬁtting are summarized in
Table S1. The release of SOD co-synthetized in water and in the TRIS
buﬀer is well-ﬁtted to the Baker-Lonsdale model (R2 0.99) indicating a
dominant role of SOD molecular diﬀusion through crystal pores. In the
case of co-synthesis in the TRIS buﬀer, the dissolution of the SOD ag-
gregates does not play a role on the initial stage of the release (as in-
dicated by rather low R2 of 0.83) and the overall release mechanism
depends solely on the diﬀusion limitations (Fig. 9a). On the contrary, in
the case of the co-synthesis in water, the ﬁrst part of the release curve
(Fig. 9b) is well-ﬁtted to the zero-order dissolution kinetics with R2
0.98. This allows one to propose that both, SOD aggregate dissolution
and SOD diﬀusion through the pores make an impact to the release
kinetics. However, considered together, these results point to the higher
stability of SOD aggregates formed for the synthesis in water compared
to the aggregates formed for the synthesis in the TRIS buﬀer.
This can be caused by stronger unfolding of the SOD molecules at
higher pH (for co-synthesis in water) leading to stronger intermolecular
SOD-SOD interactions facilitating aggregation. However, the size of the
aggregates is most probably larger for the co-synthesis in TRIS buﬀer
since the SOD content is 1.6 times higher than that for the co-synthesis
in water (Table 1). So, one can speculate that not a size of aggregates of
the protein but the strength of the aggregation will deﬁne the protein
release kinetics. Based on the ﬁndings described in this section and
above, the following section below will focus on the loading/release
mechanism of SOD.
3.6. Mechanism of SOD loading and release
Based on the results of this study, one can propose the mechanism of
SOD loading into the vaterite crystals and SOD release from the crystals.
Fig. 10 shows the schematics of these processes. SOD molecules are ﬁrst
aggregated being in the solution of CaCl2 (Fig. 10a). Mixing the solution
of SOD in CaCl2 and solution of Na2CO3 together under an intensive
stirring results in growth of vaterite crystals made of small nanocrys-
tallines (typical size tens of nm [49]) as building blocks with the pores
formed in between the nanocrystallines (Fig. 10a–b). The SOD ag-
gregates are trapped into the crystal pores. Moreover, due to a very high
content of the SOD co-synthetized in the crystals (the internal con-
centration is about 380mg/ml that is roughly a third of the SOD con-
centration in a pure solid SOD), the SOD is rather compactly packed
into the pores being in the aggregated state. In the physiologically re-
levant ionic strength (150mM NaCl), the SOD is released from the
crystals keeping its bioactivity and the release kinetics is driven the
diﬀusion of dissociated single SOD molecules through the crystal pores
(Fig. 10b–c). The complete release of SOD takes place after re-
crystallization of the vaterite crystals into non-porous calcite and is
driven by exclusion of SOD molecules from the internal volume of the
crystals upon signiﬁcant reduction of the crystal porosity. Thus, the
SOD release can be of a prolonged character due to rather slow diﬀu-
sion through the crystal pores and can be completed (release of all
loaded content) due to the recrystallization phenomenon.
3.7. Perspectives for ophthalmology
Despite the fairly large number of experimental studies on the use of
SOD for the treatment of various eye diseases, drugs based on it do not
yet exist. The only exception is the drug Erisod (later renamed Rexod-
OF). There is a patented method of treatment of open angle glaucoma
with this drug [79]. The treatment regimen is rather complicated and
consists of 6-fold instillations of the SOD solution every 5min for half
an hour. In experimental studies of the treatment of other eye diseases
using SOD (eye burns, corneal ulcers, uveitis), complex drug adminis-
tration schemes, including daily multiple (5–6 times a day) instillation
of SOD solution [25,80,81] or subconjunctival injections [23] have also
been used.
It is obvious that such complex schemes are designed to prolong the
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therapeutic eﬀect of SOD due to imperfection of the instillation route
for drugs administered, as already mentioned in the introduction, as
well as the rapid SOD elimination. Undoubtedly, the use of various
delivery systems would signiﬁcantly simplify the treatment regimen, as
well as increase its eﬀectiveness. However, the delivery systems cur-
rently described in the literature have a number of signiﬁcant dis-
advantages. Thus, pegylation of SOD signiﬁcantly lowers the perme-
ability of the enzyme through the microvessels to the area of damage
[82]. In addition, pegylation of SOD leads to the formation of hetero-
geneous products due to a large number of available amino groups on
the surface of the enzyme, which signiﬁcantly aﬀects the biodistribu-
tion and circulation times of the PEG-SOD complex in the body, as well
as its antigenic and immunogenic properties [83]. The use of liposomes
as carriers [21] also has disadvantages due to their instability (half-life
of 4.2 h) and potential toxicity [84,85]. The use of biodegradable and
biocompatible polylactoglycolic (PLG) particles based on copolymer D,
L-lactide-glycol [17] leads to the fact that the PLG-matrix makes it
diﬃcult for the substrate to access the active center of the enzyme, and
the hydrolysis of polylactoglycol can quickly deactivate enzymes in the
matrix [86]. The use of nanoparticles based on complexes of enzymes
and block copolymers [18,87] may be economically unproﬁtable due to
the high cost of copolymers and low SOD retained activity.
Recently, successful utilization of SOD (free enzyme and its con-
jugate with poly(L-lysine)-poly(ethyleneglycol) copolymer) has been
reported for the treatment of eye inﬂammation in rabbits. Signiﬁcant
elimination of the inﬂammatory signs in the eye has been demonstrated
by multiple biochemical and histological analysis [88].
Against this background, the vaterite calcium carbonate crystals can
Fig. 9. SOD release kinetics in 150mM NaCl from CaCO3 microcrystals obtained by co-synthesis in TRIS buﬀer (a) and in water (b). Mathematical ﬁtting of release
kinetics has been performed using two models: zero order kinetics (dissolution-mediated) and Baker-Lonsdale model (diﬀusion-mediated). Arrows indicate better
ﬁtting for burst release within ﬁrst 40min.
Fig. 10. Schematics of the co-synthesis of SOD-
containing vaterite crystals via mixing of SOD
molecules with CaCl2 and Na2CO3 (a–b). The
aggregation of SOD in CaCl2 results in the in-
tegration of SOD aggregates into the crystals
made of nanocrystallines as building blocks
that provides the mesoporous crystal archi-
tecture (b). Single SOD molecules are released
from the crystal in 150mM NaCl showing a
partial release (b–c). The complete release of
SOD takes place after recrystallization of the
porous vaterite into non-porous calcite (c–d)
that is accompanied by a dramatic reduction in
the crystal porosity and, as a result, the re-
duction in the hosting capability for SOD.
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be an excellent alternative system for drug delivery to the eye. On the
one hand, the synthesis of such particles is extremely simple, and the
initial components are inexpensive. On the other hand, calcium car-
bonate is completely biocompatible and biodegradable and potentially
does not possess toxic, immunogenic or any other negative responses.
Thus, in preliminary experiments, we showed that injection of vaterite
microcrystals into the eyes of rabbits at a concentration of 10mg/ml
did not cause any negative reaction (data not shown). This indicates a
high promise of vaterite crystals for ocular drug delivery. The in vivo
study on the SOD delivery into eyes via the vaterite crystals as drug
delivery vectors is in the focus of our upcoming research.
4. Conclusions
This study shows that SOD can eﬀectively be loaded into CaCO3
vaterite crystals giving extremely high content in the crystals reaching a
concentration of up to 380mg/ml (10−2 M). This is driven by Ca2+-
mediated aggregation of SOD molecules to be embedded into the va-
terite crystals during the co-synthesis. Synthesis of the crystals in TRIS
buﬀer at pH 8.4 is proven to be advantageous compared to the synthesis
in water (pH 10.3) because it allows to preserve enzymatic activity of
SOD while crystal morphology remains unaﬀected. SOD releasing from
the crystals at physiologically relevant ionic strength can keep almost
all its bioactivity during ca. 24 h under release conditions. The release
kinetics of SOD is governed by both the dissolution of SOD aggregates
and by the diﬀusion of SOD thorough the crystal pores. At the same
time, the contribution of the aggregate dissolution is higher for the co-
synthesis in water as may be explained by stronger SOD-SOD interac-
tions for protein molecules unfolded at higher pH for the synthesis in
water. The complete release of SOD is governed by the recrystallization
of porous vaterite crystals into more thermodynamically stable non-
porous calcite polymorph form. The mild aggregation of the SOD upon
co-synthesis demonstrated in this work allows to keep the enzyme
bioactive that is one of the most important criterion for SOD bio-ap-
plications. The extremely high content of SOD into the crystals makes
the crystals very attractive for therapeutic formulations with prolonged
release, also for ophthalmological purposes. The latter is supported by
ﬁrst in vivo experiments performed with rabbits and indicating no in-
ﬂammation or other reaction caused by the crystals after administration
into eyes.
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